DR. ALLEN P KAPLAN, M.D.M.D.
Osteopathic Medicine at University Blvd, Charleston, SC
License number
South Carolina 19143
Category
Osteopathic Medicine
Type
Allergy & Immunology
Address
Address
9165 University Blvd, Charleston, SC 29406
Phone
(843) 797-8162
(843) 820-1300 (Fax)
(843) 820-1300 (Fax)
Personal information
See more information about ALLEN P KAPLAN at radaris.comName
Address
Phone
17 Logan St, Charleston, SC 29401
172 Ashley Ave, Charleston, SC 29403
9165 University Blvd, North Charleston, SC 29406
1879 Savage St, Charleston, SC 29407
17 Logan St, Chas, SC 29401
Professional information
Allen P Kaplan, North Charleston SC
Specialties:
Allergist
Address:
9165 University Blvd, North Charleston, SC 29406
Board certifications:
American Board of Allergy and Immunology Certification in Allergy and Immunology, American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Diagnostic Laboratory Immunology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Dr. Allen P Kaplan, North Charleston SC - MD (Doctor of Medicine)
Address:
NATIONAL ALLERGY ASTHMA & URTICARIA CENTERS OF CHARLESTON PA
9165 University Blvd, North Charleston 29406
(843) 797-8162 (Phone), (843) 797-8372 (Fax)
9165 University Blvd, North Charleston 29406
(843) 797-8162 (Phone), (843) 797-8372 (Fax)
Hospitals:
NATIONAL ALLERGY ASTHMA & URTICARIA CENTERS OF CHARLESTON PA
9165 University Blvd, North Charleston 29406
9165 University Blvd, North Charleston 29406
Education:
Medical Schools
Suny Downstate Medical Center
Graduated: 1965
Suny Downstate Medical Center
Graduated: 1965
Plasma Prekallikrein Activation And Kallikrein Production Assay
US Patent:
6913900, Jul 5, 2005
Filed:
Aug 23, 2002
Appl. No.:
10/227234
Inventors:
Allen P. Kaplan - Charleston SC, US
Kusumam Joseph - Mt. Pleasant SC, US
Kusumam Joseph - Mt. Pleasant SC, US
Assignee:
Nippon Zoki Pharmaceutical Co., Ltd. - Osaka
International Classification:
C12Q001/37, C12N009/50, A61K035/14
US Classification:
435 23, 435219, 530384
Abstract:
A activator for prekallikrein includes isolated, purified, or substantially purified heat shock protein 90, a phosphate ion, and mixtures thereof. The prekallikrein activator is part of an in vitro system for activating prekallikrein in the absence of FXIIa. The system includes the activator, high-molecular weight kininogen, and zinc ions. A method for activating prekallikrein to produce kallikrein in the absence of FXIIa includes mixing prekallikrein with the activator and a composition comprising high molecular weight kininogen and zinc ions. A method for evaluating the activity of a test drug for the production of kallikrein comprises activating prekallikrein and determining the kallikrein produced. The activity (promoting or inhibiting ability) of the tested drug against the production of kallikrein in the absence of FXIIa can be easily measured. The test drug may be an analgesic, anti-allergy, anti-inflammatory drug.
Method For The Activation Of Blood Coagulation Factor Xii
US Patent:
6117648, Sep 12, 2000
Filed:
Sep 8, 1997
Appl. No.:
8/925167
Inventors:
Yoji Shibayama - Katoh-gun, JP
Allen P. Kaplan - Charleston SC
Allen P. Kaplan - Charleston SC
Assignee:
Nippon Zoki Pharmaceutical Co., Ltd. - Osaka
International Classification:
C12Q 156
US Classification:
435 13
Abstract:
Blood coagulation factor XII (FXII) is activated using a receptor for globular heads of the complement component Clq. The receptor (gC1qr) is a protein and provides a more faithful in vitro reproduction of the actual FX-II-activating reaction which occurs in living organisms. The protein receptor, gClqR may be obtained in at least substantially pure or isolated form by recombinant genetic engineering techniques or by isolation from animal cell membranes to which the complement component Clq binds. The receptor may be separated, purified, or isolated from cell membranes. The activation of the blood coagulation factor XII may be conducted in: 1) an animal plasma, 2) a reconstituted plasma kallikrein-kinin system, or 3) an at least substantially pure blood coagulation factor XII. The activation with the receptor is preferably conducted in the presence of zinc ions. FXII may be subjected to an activation reaction with the isolated or at least substantially purified receptor for globular heads of Clq in the presence of a pharmaceutical to evaluate or measure the pharmaceutical's inhibiting or promoting action towards the plasma kallikrein-kinin system, blood coagulation system, fibrinolysis system, renin-angiotensin system, complement system, or arachidonate cascade.